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To my daughters, Freja, Nora and Idun 
”Sometimes me think, what is friend? And then me say, friend is someone to share the last 
cookie with”  
-Cookie Monster- 
  
  
ABSTRACT 
This thesis aimed to investigate the role of thyroid stimulating hormone receptors (TSHRs) 
in adipose tissue (AT) and their role in AT dysfunction and obesity-related metabolic 
complications. Furthermore, we aimed to functionally evaluate novel candidate genes 
associated with insulin resistance, a marker of dysfunctional adipose tissue.  
Study I report that in a cohort of Swedish children with obesity, thyroid stimulating 
hormone was associated with the degree of obesity and metabolic risk markers such as 
fasting serum insulin levels and blood lipids.  
In Study II, the TSHR in AT was functionally evaluated by investigating the effect of 
partially removing TSHRs from the adipocytes on body weight and body temperature, in 
animals on both normal and high-fat diets. Mice with reduced TSHR-expression gained 
weight at a faster rate than corresponding wild-type mice. Several genes central to 
adipogenesis and adipocyte function were down-regulated, in both white AT (WAT) and 
brown AT (BAT) in TSHR knockout mice. 
Study III. From a genome-wide association study (GWAS) meta-analysis which identified 
SNPs for fasting insulin, we identified FAM13A and POM121C as novel candidate genes 
for obesity-related insulin resistance. Using expression quantitative trait (eQTL) analysis of 
SNPs associated with fasting insulin, we identified candidate genes for disease. Functional 
analysis of the candidate genes using siRNA knockdown in human mesenchymal stem cells 
revealed them to be important for lipolysis and adipogenesis and they might therefore be 
involved in the genetic control of insulin sensitivity. 
Study IV, report that expression of the TSHR in human WAT is affected by weight change. 
We also report that TSHR-expression in WAT is associated with the expression of genes 
central to adipocyte functions such as lipolysis and insulin sensitivity. The results revealed 
that, independent of BMI, individuals with higher TSHR expression had a lower basal 
lipolysis rate and higher hormone stimulated lipolysis, suggesting that TSHRs in human 
WAT are involved in the regulation of adipocyte metabolism.  
In summary, a reduction of TSHR led to dysfunctional AT regarding the regulation of 
adipocyte metabolism and adipogenesis. Our findings implicate that TSHRs have a 
regulatory role in both WAT and BAT, and thus having a role in the regulation of whole-
body energy homeostasis. Furthermore, we identified two novel genes with potential 
regulatory roles in adipocyte lipolysis and adipogenesis, and might thereby be involved in 
the genetic control of systemic insulin sensitivity.  
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Den höga förekomsten av fetma har blivit ett hot mot folkhälsan. Hos vuxna med fetma 
ökar risken för en rad följdsjukdomar, bland annat diabetes typ 2, hjärt- och kärlsjukdomar 
och cancer. Fetma är en sjukdom som definieras av överflödig tillväxt av fettväven. 
Fettväven är inte bara en vävnad som lagrar energi, den har också viktiga endokrina 
funktioner eftersom fett utsöndrar hormoner och andra signaler, till både hjärnan och 
perifera vävnader, som i sin tur reglerar kroppens energijämvikt. 
Fettväven delas in i vitt och brunt fett vilka har motsatta funktioner. Det vita fettet lagrar 
energi och vid ökat energibehov kan fettmolekyler brytas ner genom lipolys, vilket ger fria 
fettsyror som används som energisubstrat till andra vävnader. Vitt fett finns fördelat under 
huden, så kallat subkutant fett, och runt organen, invärtes fett. En ökning av mängden 
invärtes fett och subkutant bukfett, är associerat med fetmarelaterade följdsjukdomar. Brunt 
fett är en energiförbrukande vävnad som gör av med lagrad energi genom att producera 
värme och är därför ett intressant mål för fetmabehandling.  
Det övergripande syftet med avhandlingen är att få bättre förståelse för de biologiska 
mekanismer som orsakar de metabola komplikationer som fetma medför. Specifikt har den 
tyroidea stimulerande hormonreceptorn (TSHR) studerats för att utröna vilken roll den 
utgör i fettväven. Nya underliggande gener till insulinresistens har även undersökts med 
syftet att identifiera gener som på verkar fettcellens funktion och där igenom systemisk 
insulinkänslighet.  
Genom att identifiera underliggande mekanismer till fetmarelaterade metabola 
komplikationer kan nya behandlingssätt tas fram för fetma-relaterade sjukdomar. 
I Studie I undersöktes associationer mellan TSH och metabola riskfaktorer hos svenska 
barn med fetma. Vi såg ett samband mellan TSH-nivåer och metabola riskfaktorer så som 
fasteinsulin och lipidnivåer i blodet.  
I Studie II undersöktes funktionen av TSHR i en genetiskt modifierad musmodell. Vi såg 
att avsaknad av denna receptor påverkar fettvävens utveckling och funktioner som 
insulinkänslighet i vitt fett, och värmeproduktion i brunt fett.  
Studie III identifierades två nya kandidatgener som verkar påverka fettcellens utveckling 
och funktion, och därmed systemisk insulinkänslighet. FAM13A och POM121C visade sig i 
studien ha en skyddande effekt mot metabol sjukdom och kan därmed vara intressanta mål 
för behandling. 
Studie IV visade att genuttrycket av TSHR i fett hos människa, är associerat med BMI och 
även lipolys. Detta innebär att det vi såg i musmodellen kan även vara relevant i människa.  
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1 INTRODUCTION 
In this thesis I address the biological pathways in adipose tissue that are affected in 
obesity. In obesity, many molecular mechanisms become disturbed and contribute to the 
metabolic complications that follow.  
In order to study obesity-related metabolic complications, and in particular the effects of 
the thyroid stimulating hormone receptor (TSHR) in obesity, biochemical data from 
children with obesity was investigated. To functionally examine the role of the TSHR in 
adipose tissue (AT), a transgenic mouse model was used in which the TSHR had been 
reduced. To further interpret the results observed in the mouse model, gene expression 
data from adult human AT was investigated with the TSHR and its association with the 
expression of AT-specific genes as the focus.  
Furthermore, we investigated genetic determinants of insulin sensitivity. To find new 
candidate genes for insulin resistance (IR), a major risk marker for type 2 diabetes 
(T2D), we used results from a genome-wide association study (GWAS) together with 
human clinical data, adipose phenotypes and AT gene expression. The identified 
candidate genes for IR were then functionally evaluated in a cell-based model. 
1.1 OBESITY 
The prevalence of obesity has increased rapidly over the past few decades in both adults 
and children. It is a well-known fact that the obesity epidemic is now a worldwide 
health problem (1). Major contributing factors are the exposure to an obesogenic 
environment facilitating increased energy intake along with physical inactivity or 
sedentary behaviour.  
Obesity is associated with several important health problems and an elevated risk of 
developing diseases such T2D, fatty liver, cardiovascular disease and cancer (2). 
Obesity and T2D in particular are closely linked through their association with the 
development of IR (an impaired cellular response to insulin) (3). 
Why is it that our environment today, which provides sufficient food and security, is 
causing disease? Different theories have been presented in attempts to explain the origin 
of obesity. From an evolutionary perspective, genes favoring survival are selected for, 
and passed on in order to improve the survival of a species. According to the debated 
hypothesis of “thrifty genes” first presented by James V Neel in 1962, addressing the 
development of diabetes mellitus, our bodies are genetically programmed to store 
energy in order to cope with periods of limited food supply. Through selective 
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mechanisms and evolution, people with a beneficial genotype in times of need had a 
greater chance of survival. Genes favouring fat deposition are disadvantageous in 
today’s society and would thus explain the excessive weight gain that leads to obesity 
(4, 5).  
Other theories exist that contradict the “thrifty gene” hypothesis such as the “drifty 
genes” hypothesis proposed by the biologist John Speakman, in which genes favoring 
fat deposition are not selected for but are rather subjects to random drift due to the 
absence of selection by predators (6).  
Although its origin is not fully understood, the development of obesity is primarily the 
result of an imbalance between energy intake and energy expenditure, and the 
combination of a high-energy diet and sedentary behaviour appears to be the major 
cause of obesity in westernized countries. Besides eating habits and food availability, 
obesity results from a combination of genetic, epigenetic, behavioural and 
environmental factors. The influence of each trait is highly variable with a relatively 
small effect size in cause and predisposition to obesity when considered individually. 
Obesity is therefore considered a complex disease, thus requiring a multidimensional 
approach to understanding its underlying mechanisms (7). 
1.1.1 Body mass index 
Obesity is characterised by an excessive adipose tissue (AT) accumulation and is 
associated with, and usually precedes, metabolic complications. The amount and 
distribution of AT as it expands are important factors for the complications or co-
morbidities that follows obesity. Abdominal obesity is included as a risk factor in the 
metabolic syndrome and is associated with several obesity-related comorbidities and 
also considered a marker of dysfunctional AT (8, 9). 
Body mass index (BMI) is a tool used to classify an individual’s body weight in relation 
to height. BMI can be considered a proxy for body fatness and is the most widely used 
measurement to diagnose obesity. BMI is calculated by dividing an individual’s weight 
in kilograms by their squared height in metres (kg/m2), and is used to define an 
individual’s weight status. BMI is not totally height independent, taller people have a 
higher BMI. BMI weight categories are listed in Table 1.1. 
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Table 1.1 Definition of weight status by BMI 
Weight status BMI (kg/m2) 
Underweight <18.5 
Normal weight 18.5–24.9 
Overweight 25–29.9 
Obese >30 
Morbidly obese >40 
 
The metabolic risk that follows obesity cannot be evaluated by BMI alone since it does 
not reveal how the AT is distributed in the body. Furthermore, BMI dose not reveal the 
phenotype of the fat cells (adipocytes) such as adipose tissue morphology, that is the 
size and number of fat cells. The metabolic risk in obesity depends on biological 
mechanisms affected by the excessive accumulation of AT as well as the phenotype of 
adipocytes.  
1.1.2 BMI in children 
Children are growing individuals and therefore have a continuously increasing BMI. 
The use of BMI as a measure of weight status during childhood is therefore 
complicated. To be able to compare weight status during childhood, BMI can be 
transformed into a BMI standard deviation score (BMI SDS), also called z-score, using 
reference populations of healthy children. These transformations are used to define cut-
offs for obesity in children, and is a frequently used method in the clinical setting (10).  
1.2 ADIPOSE TISSUE 
AT is a heterogeneous organ consisting of several different cell types, and the interest in 
adipocytes has increased along with the obesity epidemic. The adipocyte is the body’s 
largest cell type and makes up over 90% of the AT volume but only 20–40% of its cell 
numbers (11). Other cell types in the AT are endothelial cells, fibroblasts and immune 
cells which will not be addressed in this thesis. 
The AT is an energy source for other organs and tissues and can be considered a buffer 
for changes in physiological energy demands. The ability of AT to expand and contract 
in response to an organism’s energy status is a feature assigned to the adipocytes, and is 
unique compared to other tissues (12).  
In healthy normal-weight adults, the adipose organ constitutes about 8–18% of body 
weight in males and 14–28% of body weight in females. In humans with morbid 
obesity, the adipose organ can expand up to 4 times and reach 60–70% of the body 
weight (13).  
  4 
1.2.1 Adipose tissue in children 
In the normal newborn the adipose tissue constitutes 11–16% of the body weight. At 
that time, the AT mass is mainly subcutaneous with hardly any intra-abdominal AT (14, 
15). The formation of AT begins before birth. After birth, the AT mass increase rapidly 
by lipid accumulation (hypertrophic growth) and by mitotic activity in precursor cells 
(hyperplastic growth), thus there is an increase in both size and number of adipocytes. 
In infants, there is a marked increase in AT mass compared to the growth of the other 
tissues in the body.  The AT mass is increasing about six times during the first year of 
life in comparison to the average increase in body weight being three-fold during the 
same time-period (14).  
After the first year, the increase in AT mass slows down and there is only a slight 
absolute increase of the AT. After childhood and adolescence, the AT retains the ability 
to expand during adulthood in response to excessive nutritional intake (16, 17).  
 
The AT is made up of white and brown depots (WAT and BAT). White and brown 
adipocytes have distinct characteristics and functions (18) as illustrated in Figure 1.1. 
 
 
Figure 1.1. Differences in characteristics and function of white and brown adipocytes. 
1.2.2 White adipose tissue 
WAT is the largest fat depot where metabolic energy is stored in the form of 
triglycerides (TGs). White adipocytes contain a large single lipid droplet allowing fatty 
acid (FA) storage after nutrient intake. As energy demand rises, TGs within the lipid 
droplet are hydrolysed by adipose lipases, in sequential steps, forming free fatty acids 
(FFAs) and glycerol for the use by other tissues as energy substrates, a process known 
as lipolysis. FFAs are also important for the synthesis of phospholipids and lipoproteins 
and function as signal molecules.  
White adipocyte
Nucleus
Lipid droplet
Mitochondria
Brown adipocyte
Energy storage Energy burning
  5 
Human WAT is located within specific depots that can roughly be divided into 
subcutaneous and visceral AT depots. About 80% of body fat is stored in subcutaneous 
depots and 20% in intra-abdominal, also known as visceral depots (19).  
1.2.3 Brown adipose tissue 
BAT is a much smaller part of the adipose organ and the site for non-shivering 
thermogenesis in mammals. Brown adipocytes are multilocular with many small lipid 
droplets. They are specialised cells with a high oxidative capacity due to their high 
content of mitochondria. The uncoupling protein 1 (UCP1) resides in the inner 
membrane of the mitochondria and is only expressed in brown adipocytes. UCP1, as the 
name implies, uncouples the respiratory chain from oxidative phosphorylation and 
enables the brown adipocytes to use stored energy to produce heat (20). The BAT is 
therefore an energy consuming AT depot. In mice and other small mammals, BAT-
activity generates heat to enable the animal to adapt to cold ambient temperatures (20, 
21). 
1.2.3.1 Brown adipose tissue in children and adults 
It has long been known that human infants possess BAT, with about 2-5 % of the body 
weight of infants being made up of BAT, which corresponds to approximately 150-250 
grams (22, 23). However, BAT activity and content were believed to decline quickly 
and disappear in adulthood (24).   
In 2007, it was demonstrated by using 18F-fluorodeoxyglucose combined positron 
emission tomography and computed tomography (18F PET-CT) that adult humans also 
possess active BAT (25). The findings were confirmed by several research groups, 
which also showed BAT activity to be associated with a beneficial metabolic phenotype 
(26-31). 
1.2.3.2 Thermogenesis in brown adipose tissue 
Thermogenesis is a key function of BAT. Upon stimulation, the sympathetic nerves 
innervating BAT release catecholamines acting on ß3-adrenergic receptors and lipolysis 
is induced leading to the production of FFAs. FAs directly activate UCP1 and thereby 
non-shivering thermogenesis (20).  Thyroid hormones acting on thyroid hormone 
receptors on the brown adipocyte are involved in mediating the response in BAT to 
adrenergic stimulation (32) and the control of UCP1 transcription (33). It has been 
reported that central infusion of thyroid hormone triiodothyronine (T3) increases the 
level of UCP1 in the cells. T3-induced hypothalamic AMPK inactivation leads to an 
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increased sympathetic tone in the nerves innervating BAT. Sympathetic stimulation is 
the physiological mechanism for BAT recruitment (20, 25). The binding of TSH to 
TSHRs on brown adipocytes is also involved in the formation of BAT probably by 
regulating UCP1 and other factors involved in browning (34). 
No mechanism other than UCP1 can mediate non-shivering thermogenesis, giving BAT 
an essential role in energy expenditure (35). Given its potential to stimulate energy 
expenditure and being associated with protection against obesity and metabolic 
comorbidities like T2D, BAT has become a potentially and interesting target in obesity 
treatment. 
1.2.4 Adipogenesis 
Adipose tissue expands by enlargement of existing mature adipocytes or the generation 
of new adipocytes by differentiation of precursor cells into mature adipocytes, a process 
known as adipogenesis (14, 36). Adipose precursor cells are present in the stromal 
vascular fraction of the AT (37). 
Brown and white adipocytes require key transcription factors to promote differentiation. 
Peroxisome proliferator-activated receptor-gamma (PPAR), a member of the PPAR 
family of transcription factors (TFs), is considered the master regulator of adipogenesis 
(38). CCAAT/enhancer-binding proteins (C/EBPs) are a family of transcription factors 
with key regulatory roles in adipogenesis (39).  
Adipose tissue growth occurs through the accumulation of lipids and expansion of the 
adipocyte. During overnutrition and the development of obesity, the AT undergoes 
dynamic changes. When lipids are stored, pre-existing adipocytes expand and new 
adipocytes are produced by proliferation and differentiation of preadipocytes into 
mature adipocytes (36, 40, 41). 
1.2.5 Adipose tissue morphology 
Adipocyte morphology, that is the relationship between adipocyte size and number of 
adipocytes, is an important factor affecting obesity-related metabolic risk. The adipose 
tissue expands by increasing the volume and number of adipocytes causing distinct 
morphologies termed hyperplasia (many small adipocytes) or hypertrophy (few large 
adipocytes), (Figure 1.1). Adipose tissue morphology is independent of total body fat 
(42). 
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Figure 1.2. Adipose tissue expansion in overnutrition. Hypertrophic AT is associated 
with impaired adipocyte function an increase in metabolic risk. 
 
The manner in which the AT expands can influence metabolic health. When the AT 
undergoes excessive expansion, it is followed by hypoxia, fibrosis and macrophage 
infiltration. The macrophages release a number of pro-inflammatory signal molecules 
which contribute to a detrimental metabolic phenotype. Hypertrophy is associated with 
IR (43) and T2D (44) independently of the degree of obesity. Increased adipocyte size 
correlates with impaired adipogenesis, due not to a lack of precursor cells but to the 
impaired ability to induce commitment of precursor cells to the adipose lineage and 
differentiation to mature adipocytes.  
Reduced adipogenesis is seen in individuals with IR (42, 45). In BMI-matched 
individuals, IR-individuals had a larger proportion of hypertrophic adipocytes in SAT as 
compared to insulin sensitive individuals (46). Larger adipocytes blunted the ability of 
insulin to stimulate fat synthesis through glucose conversion into lipids (lipogenesis), 
which leads to an increased influx of FFA to the liver and systemic IR (47, 48).  
The lipolytic activity in adipocytes is a determinant of insulin sensitivity and is altered 
in obesity. Hypertrophic adipose morphology is also shown to be positively correlated 
to total cholesterol and triglycerides (TGs). Visceral adipose morphology has been 
associated with metabolic disease and hypertrophic visceral fat is associated with higher 
plasma levels of lipids compared to hyperplastic VAT (49). 
It has been shown that improving insulin signalling in adipocytes improves systemic 
metabolic homeostasis, implicating adipocyte IR as a promising target for treatment of 
obesity-related metabolic disease (50). 
Cell size ↑
FFA release ↑
Inflammation ↑
Insulin sensitivity ↓
Cell number ↑
FFA release ↓
Inflammation ↓
Insulin sensitivity ↑
Overnutrition
Adipose tissue
expansion
Hypertrophy
Hyperplasia
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1.3 FUNCTIONS OF THE ADIPOCYTE 
1.3.1 Lipolysis 
Lipolysis is a complex process within the adipocyte, where enzymes (lipases) hydrolyse 
TGs into free fatty acids (FFAs) and glycerol) (51). FAs are energy-rich molecules and 
deliver fuels for peripheral tissues such as heart, liver and skeletal muscle, where they 
are oxidised to yield ATP. ATP is the energy-currency of our bodies, carrying the 
energy that is used in all the cells of the body (51). 
Lipid turnover in AT, that is uptake and release of FAs, has a central role in energy 
metabolism and is closely related to body-fat mass. It is known that, in the obese state, 
basal lipolysis rate is increased but hormone-stimulated lipolysis is decreased (51), 
indicating that lipolysis has a central role in metabolic complications in obesity.  
Lipolysis is tightly regulated by multiple hormonal and biochemical signals. Substances 
that regulates cyclic adenosine monophosphate (cAMP) levels in the adipocyte are 
direct regulators of lipolysis, whereby an increase in cAMP stimulates lipolysis and 
inhibition of lipolysis is associated with reduced levels of cAMP (52).  
A large number of substances regulate cAMP levels and thus lipolysis. In adults, 
catecholamines have a pronounced and immediate lipolytic action, and the lipolytic 
action of catecholamine is mediated by β-adrenergic receptor subtypes: β1, β2, and β3. 
In human AT, β1 and β2 are most active whereas in rodents β3 is the most active 
adrenergic receptor. In both humans and rodents, β3-adrenergic receptor is active in 
BAT. A fourth receptor is present in human AT, α2A-adrenergic receptor, which 
inhibits lipolysis when bound to its ligand (51). 
The β-adrenergic receptors are G-protein-coupled receptors that, when activated, trigger 
a signalling cascade in the cell (Figure 1.3). The binding of a ligand to its β-adrenergic 
receptor produces cAMP from adenosine triphosphate (ATP), catalysed by adenylyl 
cyclase (AC), increasing the cAMP level in the cell. This activates protein kinase A 
(PKA), which phosphorylates the lipid droplet proteins hormone sensitive lipase (HSL) 
encoded by LIPE, and perilipin encoded by PLIN, which in turn activates adipose 
triglyceride lipase (ATGL). The activation of cAMP-AC pathway is also involved in the 
regulation of gene transcription in the nucleus of genes involved in proliferation and 
inflammation (53, 54). 
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Figure 1.3. Catecholamine-stimulated G-protein coupled receptor activation of the 
cAMP cascade. 
 
Adipose lipolysis is interesting due to its association with fat mass and its central role in 
energy homeostasis. A recent study by Arner et al (2018) (55) reported that 
subcutaneous fat cell lipolysis was linked to long-term weight gain in adult women as 
well as IR and the development of T2D. It is possible that variations in basal and 
hormone-stimulated lipolysis in adipocytes may affect the individual’s predisposition to 
obesity. 
Other substances that have more recently been shown to stimulate lipolysis are 
natriuretic peptides although they are thought to be involved in lipolysis under other 
conditions than obesity such as cancer cachexia (56, 57). 
1.3.1.1 Regulation of lipolysis during childhood 
In human newborns, thyroid stimulating hormone (TSH) is the dominating lipolytic 
hormone. (58, 59). As the child grows older, the lipolytic effect of TSH is reduced and 
catecholamines becomes the main lipolytic regulators (58, 60). TSH and catecholamines 
are ligands to G-protein coupled receptors and the TSH receptor is described in detail in 
section 1.4. 
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1.3.2 Insulin action in adipocytes 
Insulin is a major anabolic hormone in the body and regulates energy metabolism 
through the activation of glucose uptake in both adipose tissue and skeletal muscle. 
Insulin is a peptide released from the pancreatic beta cells in response to a rise in blood 
glucose level after a meal. When the insulin receptor is activated, glucose transporter 
type 4 (GLUT4), a protein encoded by the SLC2A4 gene, is translocated to the cell 
surface and glucose is taken up by the cell (Figure 1.4) (61).  
 
 
 
Figure 1.4. Insulin signalling and glucose uptake. 
 
Insulin also inhibits lipolysis by inactivation of cAMP in the adipocyte and stimulates 
lipogenesis, resulting in TG synthesis by glycerol esterification with FAs (62). 
Furthermore, insulin has a systemic effect on glucose levels by inhibiting 
gluconeogenesis in the liver (63).  
In muscles and the liver, the intracellular accumulation of lipids (diacylglycerols) 
triggers the activation of protein kinases C followed by impairment of insulin signalling. 
This hypothesis accounts for one of the mechanisms behind the development of insulin 
resistance in obesity-related T2D (64). 
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1.3.3 Adipose tissue is an endocrine organ 
The adipose tissue does not only store energy for future energy demands, it is also a 
dynamic endocrine organ with a major role in regulating whole-body energy 
homeostasis. Adipocytes are metabolically active cells that cross-talk with their close 
environment and peripheral tissues through endocrine and paracrine signalling. They 
release a large number of signalling molecules known as adipokines involved in the 
regulation of many biological functions such as appetite, inflammation, glucose and 
lipid metabolism and reproduction (65, 66).  
1.3.3.1 Leptin 
Leptin is an adipokine encoded by the LEP gene and is secreted into the circulation. It 
acts as a lipostatic, negative feedback signal (a signal that regulate energy intake and 
expenditure through signalling between the AT and the brain. Several studies have 
shown leptin to reduce food intake, body mass and body fat and also to increase energy 
expenditure and restore euglycemia (67-69). In humans, there is a strong positive 
association between circulating leptin levels and body-fat mass, which can be explained 
by larger adipocytes releasing more leptin than smaller ones (70). Leptin is now a well-
studied adipokine and known as a regulator of energy intake and storage. 
1.3.3.2 Adiponectin 
Adiponectin is an adipokine produced by the AT and released into the blood. There is 
an inverse association between plasma levels of adiponectin and human fat mass, and 
reduced levels of adiponectin are associated with the development of T2D (71). In 
obesity, plasma levels of adiponectin are reduced and the administration of adiponectin 
in diet-induced obesity models has been shown to improve insulin sensitivity  (72, 73).  
In addition to leptin and adiponectin, AT and adipocytes secrete several other 
adipokines and cytokines. 
1.3.4 Adipose tissue inflammation 
The immune system is closely linked to the metabolic system. It is well established that, 
in obesity, when the AT undergoes excessive expansion, inflammatory cells are 
infiltrated into the adipose tissue and inflammatory cytokines are released into the 
circulation (74). This results in a low-grade systemic inflammatory state which 
contributes to metabolic complications such as IR (75, 76). Three important 
proinflammatory secreted adipokines are investigated below.  
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1.3.4.1 TNF-alpha 
Tumour necrosis factor alpha (TNF) is a well-studied cytokine mainly secreted by 
macrophages in the AT but also by adipocytes (77). It is believed that TNF acts locally 
in AT in a paracrine or autocrine manner. It is also believed that the TNF  affects 
insulin action distal to the insulin receptor, since it reduces maximal insulin 
responsiveness and not basal glucose transport (78).  TNF levels are elevated in 
obesity and inversely associated with insulin sensitivity (79). TNF has previously been 
shown to stimulate lipolysis in adipocyte cell lines (80) and inhibit insulin-stimulated 
lipogenesis in the AT from obese women (79). TNF-knockout mice are resistant to 
obesity-related IR, probably due to the inhibitory effect of TNF on gene expression of 
the insulin receptor, insulin receptor substrate 1 (IRS1) and SLC2A4, encoding GLUT4 
(81, 82).  
1.3.4.2 IL-6 
Interleukin-6 (IL-6) is a proinflammatory cytokine associated with obesity (83). IL-6 is 
positively associated with BMI and impairs insulin sensitivity in humans (84). In T2D 
patients, elevated IL-6 levels were predictive of the development of T2D. In obesity, 
when the macrophages are infiltrated into the AT, IL-6 is believed to contribute to IR.  
1.3.4.3 CCL2 
Monocyte chemoattractant protein 1 (MCP-1) encoded by the CCL2 gene, is another 
pro-inflammatory cytokine secreted by cells in the AT. It contributes to the chronic 
inflammation seen in obesity by stimulating macrophage infiltration into the AT. CCL2 
levels are increased in the obese state (85). Both humans and mice with obesity have 
increased CCL2 expression in their WAT (86), and at least in mice, the elevated CCL2 
level is sufficient to induce inflammation in the AT, and affect insulin sensitivity (87).  
1.4 THYROID STIMULATING HORMONE  
Other endocrine factors than catecholamines and insulin that also regulate adipose tissue 
function are thyroid stimulating hormone (TSH) and thyroid hormone triiodothyronine 
(T3).  
Thyroid hormones are central players in the regulation of our metabolism. They control 
body functions such as body weight (88), heart rate (89), respiratory capacity (90) the 
nervous system (91) and more. 
The main biological function of TSH and its receptor, thyroid stimulating hormone 
receptor (TSHR), is to control the release of thyroid hormones T3 and thyroxine (T4) 
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from follicular cells in the thyroid gland. TSH is involved, both directly (92-94) and 
indirectly via thyroid hormones (95), in the regulation of basal metabolism (88, 95, 96).  
In the thyroid gland, the TSHR regulates the production and release of thyroid 
hormones. Circulating thyroid hormone levels are regulated by negative feed-back on 
the hypothalamic-pituitary-thyroid axis (Figure 1.5). Release of TSH from the pituitary 
gland is initiated by thyroid releasing hormone (TRH) from the hypothalamus. TSH 
binds to the TSHR on the thyroid gland, which leads to the synthesis and release of T3 
and T4. T4 is further enzymatically converted by deiodination to active T3 in peripheral 
tissues. T4 and T3 suppress the release of TRH and TSH respectively, by negative 
feedback regulation, on the hypothalamus and the pituitary gland (97). 
 
 
Figure 1.5. Feedback regulation of thyroid hormones. 
Sub-clinical hypothyroidism, a condition in which the thyroid gland fails to produce 
normal amounts of thyroid hormones and TSH levels are increased in order to restore 
normal levels (98), is associated with weight gain, cardiovascular disease and IR (99, 
100). Furthermore, sub-clinical hypothyroidism is a condition associated with a pro-
inflammatory state and IR, where an elevation of pro-inflammatory proteins such as IL-
6 and elevated FFAs has been reported (101, 102). 
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1.4.1 Thyroid stimulating hormone and obesity 
Body composition and TSH are closely related (103). TSH, via its stimulatory effect on 
the release of thyroid hormones, is involved in the regulation of energy metabolism and 
thermogenesis (93, 95) and also in glucose and lipid metabolism (88).   
In adults with obesity, TSH has been reported to be elevated, although results indicating 
unaltered TSH and thyroid hormones have also been presented (104, 105). A positive 
correlation between weight gain over 5 years and a progressive increase in TSH level 
have also been reported. Even slightly elevated TSH levels might be involved in the 
occurrence of obesity (106), but the cause of the higher TSH concentrations observed in 
the obese state, and the underlying mechanisms are unclear (107, 108). 
1.4.2 Thyroid hormones and effect on energy balance.  
Thyroid hormones regulate energy expenditure by regulating cellular respiration (109, 
110).  Thyroid hormones act on the hypothalamus, modulating AMPK activity, 
increasing the activity of the sympathetic nervous system and thereby regulating whole-
body energy homeostasis. Centrally administered T3 also upregulates thermogenic 
markers in BAT (111).   
The relationship between obesity and the thyroid is complex and it is still not known 
whether changes in thyroid function are primary or secondary to obesity (106, 112). 
Hyperthyroidism (thyroid hormones fT3 and fT4 above the normal range and/or TSH 
below the normal range) is known to predispose to weight loss and hypothyroidism to 
induce weight gain, due to the role of thyroid hormones in thermogenesis and appetite 
regulation (88, 95). Overfeeding increases, and undernutrition decreases energy 
expenditure due to the related increased or decreased concentrations and production rate 
of T3 (113).  
Resting energy expenditure is positively associated with T3 levels and it has been 
suggested that an increase in TSH and secondarily in fT3 in obesity is an attempt to 
increase resting energy expenditure and inhibit the storage of excess energy into fat 
(110). In other words, TSH in obesity may be increased as an adaptation to the 
excessive weight gain (88, 95).  
Sub-clinical hypothyroidism is reported to be associated with components of the 
metabolic syndrome such as glucose tolerance (114, 115). Underlying mechanisms 
involves effects of T3 on insulin signalling, β-cell function, gluconeogenesis in the 
liver, lipolysis and lipid oxidation as reviewed (116). These factors raise the question of 
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whether thyroid hormones in the upper normal range in the obese state, might have an 
impact on adipocyte function. 
1.4.3 Thyroid stimulating hormone receptor in adipocytes 
In adipocytes from human neonates, TSHRs regulate lipolysis through the binding of 
thyroid stimulating hormone (TSH). TSH is the dominating lipolytic hormone when the 
lipolytic effect of catecholamines is depressed by an increased alpha-2 adrenoceptor 
activity. (58, 59). As the child grows older the lipolytic effect of TSH is reduced and 
catecholamines acting on β-adrenergic receptors becomes the main lipolytic regulators 
(58, 60). 
TSHRs were thought to be confined to the thyroid gland; however, it has been proven 
that they are widely expressed and functional in extra-thyroidal tissues such as human 
and rat adipocytes (117, 118). Studies have also demonstrated the presence of functional 
TSHR in adult human adipose tissue (117, 119) but their physiological significance and 
role in adipocytes is still largely unknown.  
Studies in preadipocyte cell lines (120) and animal models (118) suggest that TSHRs 
are involved in white AT (WAT) proliferation and differentiation of white adipocytes 
(121). In a small study of adult human AT, the levels of TSHR expression decreased 
during adipogenesis (122). In brown adipose tissue (BAT) TSHRs are suggested to be 
involved in the regulation of thermogenesis (93), thereby having an effect on energy 
homeostasis.  
More recently in a mouse model with AT-specific knockout of TSHR, it was shown that 
the knockout mice had larger adipocytes compared to controls (123). This finding 
supports the descriptive results in studies of human AT that TSHR activation may 
contribute to body composition separately from the effect of circulating thyroid 
hormone levels (103). 
Although the level of TSHRs is reduced in adults compared to children, more recent 
studies on adult AT report that the expression of TSHRs is altered when the AT 
undergoes excessive expansion, as in obesity (120, 124).  
In brown adipocytes, the expression of TSHR has been clearly established, but the 
physiological role of TSHR in BAT is yet to be established.  Mice harbouring a 
mutation in the TSHR, are hypothyroid because of the mutation. Studies have indicated 
that not only thyroid hormones but also TSH might be directly involved in the 
regulation of UCP1-expression in mouse BAT (93).  
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Mouse strains that lack either functional TSH or TSHR display hypothyroidism with 
thyroid hyperplasia. These strains exhibit dysfunctional TSHR in all body tissues, and it 
is therefore not possible to study the direct role of TSHR in a specific tissue, such as 
AT. Thus, in order to study the specific role of the TSHR on adipocyte function, a 
mouse model with normal thyroid function but with specifically down-regulated 
expression of TSHR in AT was generated by our research group (123). 
We used the Cre-lox system to specifically remove a part of the gene coding for the 
TSHR in adipose tissue (TSHR loxP/loxP/Cre + or TSHR KO). This provides an advantage 
compared to other TSHR knockout mice strains, in which the TSHR is non-functional in 
all cells. The TSHR KO mouse has functional TSHRs in all tissues except BAT and 
WAT. The initial characterisation has shown that the TSHR KO mouse is euthyroid and 
healthy. The TSHR expression is reduced in WAT and BAT and the lipolytic effect of 
TSH in vitro is low (125). In contrast, the expression of TSHR in other organs, such as 
brain, muscle and kidney, are similar in TSHR KO and wild-type (WT) mice. At 8 
weeks of age, the white adipocytes were larger in TSHR KO than in WT animals which 
further supports the hypothesis that functional TSHRs in adipocytes are of physiological 
importance for adipocyte growth and function. Our results indicate that TSHRs are of 
importance for BAT since UCP1 expression is lower in TSHR KO animals and whole-
body temperature is also significantly lower in young animals. These results indicate 
that TSH-TSHR signalling in brown adipocytes is essential for normal functioning of 
the UCP1, body temperature regulation and body weight in early life. 
1.5 OBESITY: A COMPLEX DISEASE 
Obesity is a complex disease. Complex diseases are called “complex” because both 
genetic and environmental factors contribute to susceptibility risk. It is possible that 
individuals that are genetically predisposed to develop obesity and obesity-related 
complications are at greater risk by living in an obesogenic environment by so called 
gene-environment interactions. 
1.5.1 Dysfunctional adipose tissue 
In humans, the physiological link between obesity and metabolic disease is currently not 
fully understood. One proposed factor is the AT-expandability hypothesis (126). When 
the AT undergoes excessive expansion, as in obesity, it changes its hormonal secretion 
patterns as well as its sensitivity to signal molecules. Furthermore, the development of 
hypoxia, oxidative stress, fibrosis and inflammation contribute to the AT becoming 
dysfunctional (127-129). The capacity of AT to expand is considered to be limited for a 
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given individual. When this limit is exceeded, lipids begin to accumulate in ectopic 
tissues causing lipotoxicity leading to IR and metabolic dysfunction (126).  
Lipolytic products such as diacylglycerols (DAGs), monoacylglycerols (MAGs) and 
FFAs not only serve as energy dense substrates for other tissues, they are also signalling 
molecules involved in multiple biological pathways (130). In obesity, excessive FFAs 
produced by lipolysis enters the circulation and are transported to peripheral tissues. 
Therefore, FFAs released from the AT are likely to be key factors in ectopic lipid 
accumulation in obesity. Studies in humans report that FFAs attenuate insulin-
stimulated glucose uptake and oxidation in peripheral tissues, thereby contributing to IR 
(131, 132). A dysfunctional lipolysis is likely to be a factor contributing to obesity-
related metabolic complications and adipose morphology is linked to functions in the 
adipocyte such as lipolysis.  
The reasons and mechanisms behind why some but not all individuals with obesity 
develop metabolic complications are still unknown. For instance, not all individuals 
with obesity develop a severe IR (133). There seems to be a strong genetic influence 
underlying adipose morphology, seen in studies of twins with concordant BMI (134),  
indicating a genetic variation in the predisposition of developing obesity-related 
complications. More research is needed to clarify what underlying mechanisms causes 
the altered adipocyte function in hypertrophic obesity. 
1.5.2 Genetic predisposition 
Genetic predisposition is one cause for the development of obesity and obesity-related 
disease. Genome-wide association studies (GWAS) have led to the discovery of 
numerous genetic variants such as single nucleotide polymorphisms (SNPs) associated 
with risk markers for various diseases.  
In the past few years, GWASs led to the discovery of numerous genetic risk markers for 
obesity traits. The first locus for BMI, was identified in 2007 and was located in the 
FTO gene (135, 136). Taken together, <3% of variation in BMI in the population is 
explained by identified genetic loci (137).  
Concerning T2D, heritability is estimated to range between 30–70%, based on twin 
studies (138). According to the DIAGRAM consortium, a research collaboration 
performing large scale studies to characterise the genetics of T2D, estimated that known 
genetic variation account for around 50% of the risk for a diabetes-related trait (139).  
To further identify genetic loci for complex disease, methods for deep sequencing of all 
known exons have been developed with the capacity to detect low-frequency and rare 
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causative variants in the genome (140, 141). These studies are a major tool for 
identifying genes that contribute to complex diseases in which many different variants 
contribute to disease susceptibility, with each variant having only a subtle effect. 
However, large gaps remain in understanding the heritable genetic impact of detected 
genetic variation on obesity.  
For the majority of loci discovered by GWASs, the probable disease-causing genes 
remain unknown (137). Since lead SNPs often resides in non-coding regions in the 
genome, expression quantitative trait loci (eQTLs) of genes in the vicinity of SNPs 
associated with obesity and obesity-related traits could lead to the finding of candidate 
genes with a functional impact on disease (142).  
Adipose tissue eQTL studies, with gene expression levels of target genes in adipose 
tissue investigating genotype-gene expression level correlations, have implicated genes 
involved in obesity and metabolic traits. The importance of genetic influence in the 
susceptibility to T2D is well established (143), but large gaps remain in our 
understanding of how genetic variations affect molecular processes and thereby 
contribute to T2D susceptibility. GWASs have identified several genetic loci associated 
with fasting insulin (FI) and FI adjusted for BMI (144). However, for most of these 
associations the functional impact of the genetic variation in the loci is unclear. 
Associations of gene expressions in the AT with human clinical traits could identify 
candidate genes causing the metabolic trait (78). It is important to understand the 
molecular changes that comes with obesity in order to further understand how different 
treatments may potentially contribute mechanistically in obesity-related disorders. 
Functional studies of candidate genes from GWAS are needed to clarify their 
physiological impact and what mechanisms are affected in obesity and adipose tissue 
hypertrophy and the accompanying metabolic risk. 
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2 HYPOTHESES AND AIMS 
2.1 SPECIFIC AIM OF THE STUDIES 
2.1.1 Study I 
Research has shown that thyroid stimulating hormone levels are affected in obesity. It is 
unclear what causes elevated TSH-levels in obesity and whether they influence 
metabolic health. In Study I, we aimed to investigate if TSH status within the normal 
range is associated with degree of obesity and metabolic risk markers in children with 
obesity. We hypothesised that TSH levels are increased within the normal range to 
maintain normal thyroid hormone levels, and that a high-normal TSH is accompanied 
by a more deranged metabolic profile. 
2.1.2 Study II 
TSHR has been implicated to have a role in adipogenesis and in the regulation of 
adipocyte functions. In Study II, we set out to investigate the AT-specific role of TSHRs 
using an AT-specific knockout mouse model. We aimed to investigate how TSHRs may 
contribute to adipocyte function in different AT depots in the nutritionally obese state 
and in the normal-weight state. We hypothesised that reduction in the effect of TSH, a 
potent lipolytic hormone, should affect fat cell metabolism. 
2.1.3 Study III 
In Study III, we set out to investigate the impact of candidate genes in genetic loci 
associated with fasting insulin, on adipogenesis and adipocyte function. The key 
research question was: can identified candidate genes in these genetic loci be linked to 
adipose variables, thus linking adipose function to systemic insulin resistance? 
2.1.4 Study IV 
Given that TSHRs are known to be down-regulated in obesity and are proposed to have 
a regulating role in adipogenesis. Larger fat cells have been reported when TSHRs are 
knocked out in the adipose tissue of mice. Therefore, in we aimed to investigate TSHR 
expression in WAT in relation to BMI and WAT phenotypes (WAT morphology, 
lipolysis and insulin-stimulated lipogenesis). In addition, we investigated if TSHR 
expression in WAT is connected to expression of adipocyte genes central to 
adipogenesis, adipocyte lipolysis, insulin signalling and genes encoding adipokines. In 
individuals with morbid obesity we aimed to investigate if the reduction of TSHRs in 
obese WAT is a primary effect or if TSHR expression is affected by weight change in 
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women with obesity. We hypothesised that TSHR-expression in human WAT, is 
affected by weight change and that TSHR signalling in WAT is associated with 
adipocyte metabolism. 
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3 RESEARCH APPROACH AND REMARKS ON THE 
METHODS 
The methods and materials used for each study have been described in detail in their 
corresponding papers. In this chapter, study designs are described in brief and interesting 
aspects of a few selected methods are addressed.  
3.1 STUDY I 
3.1.1 The Swedish Childhood Obesity Register (BORIS) 
In Study I, data from the BORIS register was used to investigate TSH levels in children 
with obesity and the association of TSH with metabolic risk markers. BORIS is a national 
web-based quality register for childhood obesity treatment supervised by the National 
Board of Health and Welfare. It was started in 2005 with the purpose to quality assure the 
pediatric obesity care and to be a tool for the health care staff. Since 2005, over 18000 
children with different severity of obesity, at different ages and follow-up times, have been 
included in the register and BORIS. The register is therefore a good source for clinical 
research. 
3.1.2 Study design 
The study encompassed a retrospective cohort design consisting of children registered in 
BORIS. The children and adolescents were enrolled in obesity treatment from pediatric 
clinics all over Sweden between August 1995 and June 2016. Inclusion criteria were 
children and adolescents classified as obese according to Cole and Lobstein (2012) (10) 
with records of TSH levels within the normal range (Age 3-6.9 years TSH 0.7-6.0 mU/L; 7-
11.9 years 0.6-4.8 mU/L; 12-17.9 years TSH 0.5-4.3 mU/L (Reference intervals for 
children and adults, Elecsys Thyroid Test Elecsys 2010 syst. Roche Diagnostics 2009)). 
Exclusion criteria were: diagnosed thyroid disease (subclinical and overt hypo- and 
hyperthyroidism, Graves’ disease, Hashimoto’s thyroiditis, and thyroid hormone treatment 
in general), the presence of hypothalamic or pituitary disturbances, central nervous system 
damage, or syndromes (Prader-Willi syndrome, Down syndrome, and Laurence-Moon-
Bardet- Biedl syndrome) or other chronic diseases. In Study I, we set the inclusion criteria 
as described in the flow chart (Figure 3.1). 
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Figure 3.1. Flow-chart of inclusion. 
After exclusion, a total of 3,459 children, aged 3.0–17.9 years, were identified within each 
age-specific normal TSH range.  
3.1.3 Metabolic risk markers 
Fasting blood samples were obtained from all children, and routine biochemical analysis 
was performed to obtain their levels of TSH, free T3, free T4, fasting insulin, fasting 
glucose and blood lipid. The homeostatic model assessment of insulin resistance (HOMA-
IR) was calculated by the formula:  
(fasting glucose (mmol/L) x fasting insulin (mIU/L))/22.5  
HOMA-IR is a model used to estimate an individual’s IR (145). However, there is no 
unanimous defined cut-off for IR and values above 2.3–2.5 are often defined as IR and 
values <2.0 are considered normal (146).  
3.1.4 Statistical analysis 
Linear regression analyses were conducted to investigate associations between TSH and 
BMI, and between TSH and metabolic risk markers. The models were adjusted as 
appropriate for BMI, sex and age. One study by Ittermann et al., has shown that smoking 
may mediate the association between thyroid function and BMI in adolescents (147). They 
found the relationship to be stronger in smokers than non-smoker. One could therefore 
suspect smoking to be a cofounder in this study. We did not have information about 
smoking status of the children and adolescents included and could not take in account this 
Subjects in database
n=18 448
n=4027
Not fitting age criteria n=411
n=3 937
n=3 564
Included
n=3 459
TSH missing n=14 010
Not classified as having obesity
n=373
Syndromes and chronic diseases
n=105
n=18 037
TSH not eligible or not within
normal range for age n=90
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possible cofounder. However, most individuals in the study are children where smoking is 
uncommon. 
It should be noted that statistical associations do not imply causality, especially in 
multifactorial conditions and biological processes such as metabolism. They do however, 
generate research questions for future research. 
3.1.5 Ethical permission   
Data collection in BORIS was obtained by the regional committee of ethics in Stockholm 
(2014/381-31/5). 
3.1.6 Comments on the design 
Study I was a retrospective cross-sectional study. A prospective design would have been 
preferable since no causal relationship can be determined in a cross-sectional study. 
Furthermore, the cut-off for “high-normal TSH” is under debate and different cut-offs for 
elevated TSH have been used previously. This may be a problem due to difficulties in 
directly comparing our results to previous studies. An elevated TSH level is described in 
some studies as 4.0–10.0 mU/L (148, 149), whilst others suggest that the limit should be 
lower (150). Recently, TSH >3.0 mU/L is described as elevated within the normal range 
(151) and supports the cutoff chosen in the present study.  
3.2 STUDY II 
In Study II, we used genetically modified mice to study the impact of an AT-specific TSHR 
knockout on AT development and function. Using in vivo animal models provides a way to 
study a factor or condition in the physiological context.  
3.2.1 Study design 
3.2.1.1 Mice and diet intervention 
At 4–5 weeks of age, male animals were divided into 4 groups according to genotype and 
diet. TSHR knockout and corresponding wild-type mice received either a high-fat diet (60% 
kcal from fat) or a matched control diet (10% kcal from fat) for 20 weeks. 
3.2.1.2 Physiological measurements 
Physiological phenotypes were determined by measurements of body weight and body 
temperatures Measurements were performed in the morning at the environmental 
temperature of 20–22C.  
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3.2.1.3 Glucose tolerance test 
Glucose tolerance was investigated in a group of female mice both at baseline, at 8 weeks 
of age, and after 10 weeks (follow-up test) on either a control diet or high-fat diet. They 
received an oral glucose dose of 1.5 grams of glucose per kilogram of body weight as a 
20% aqueous glucose solution (Glucose, APL Pharma Specials, Sweden). Blood was drawn 
from the tail vein before glucose administration and at 15, 30, 60, 90 and 120 minutes after 
dose. Plasma glucose was measured in connection with each blood sample using a 
glucometer (HemoCue system, Hemocue AB Ängelholm, Sweden). 
3.2.1.4 Gene expression analysis in white and brown adipocytes 
After 20 weeks, interscapular BAT and epididymal WAT fat depots were collected and  
isolated adipocytes were prepared using the collagenase method (152) to ensure that the 
following gene expression analysis was conducted on adipocytes and not on AT, which 
contains several other cell types.  
Gene expression of selected genes in adipocytes was determined by real time PCR (CFX 
thermocycler, BioRad) using Taqman assays (Life Technologies). TSHR-expression was 
investigated in both white and brown adipocytes.  
In white adipocytes, the expression of genes central to adipogenesis, lipolysis, insulin 
sensitivity, and adipokine/cytokine-signals were investigated. In addition, in brown 
adipocytes, genes central to BAT function, such as thermogenesis, were investigated.  
All gene expression assays were normalised against GAPDH. Relative gene expressions 
were calculated using the delta-delta Ct method (153) and expressed as fold-change in the 
expression of target genes relative to untreated controls (TSHR knockout on control- and 
high-fat diet and wild-type on high-fat diet relative wild-type on control diet). 
3.2.2 Statistical analysis 
Between-group comparisons were performed using an independent t-test for sample sizes 
≥6 (body weights and body temperatures). One-way ANOVA with the Bonferroni posthoc 
test was used to compare calorie intake and relative gene expressions. p<0.05 was 
considered significant. No adjustment for multiple testing was applied since the gene 
expression analysis were investigated with specific hypotheses for adipogenesis and 
adipocyte-specific functions. 
3.2.3 Ethical permission 
The study protocol has been approved by the Stockholm South Animal Board Ethics 
committee (D.no S65-13, D7-16).   
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3.2.4 Mice as a research model  
3.2.4.1 Mice versus humans 
Rodents are a widely used pre-clinical model for human obesity. There are, however, 
several differences between rodents and humans when it comes to AT physiology that 
needs to be considered when deciding whether the research findings can be translated to 
humans. Beneficial aspects of using an animal model are that non-biological factors, that 
are considered to be confounders in human studies, can be excluded. Ethnicity, 
socioeconomics, education and environmental exposure are factors that would need to be 
considered in human studies. A mouse model is also a good alternative to cell lines since an 
animal displays greater biological variation than cell cultures. 
3.2.4.2 Adipose tissue depots 
As in humans, AT in mice is divided between different depots, however, the location of 
these depots differs between humans and mice (18). The perigonadal fat in mice, also 
known as the epididymal fat in male mice and periovarian fat in female mice, is often used 
in AT studies in mice, partly because it is easy to isolate. However, there is no 
corresponding fat depot in humans and, as different fat depots have been shown to differ in 
certain functional aspects, this needs to be considered. 
In humans, a sexual dimorphism in both total adiposity and depot-specific adiposity exists 
(154). The sexual dimorphisms are less well-documented in rodents. However, similar to 
humans, female mice have a greater total fat mass than male mice but remain the insulin 
sensitivity remains. There are however, inter-depot differences in insulin sensitivity in 
female mice that do not correspond to humans (155).  
Weight-loss studies in mice and humans display a similar fat-depot pattern when it comes 
to which depots are reduced (156-158). Hypothetically, this may indicate that weight gain 
also occurs in a similar way between depots in mice and humans.  
3.2.4.3 Lipolysis 
Lipolysis can be stimulated in mice and humans under similar physiological conditions and 
by similar activation of the sympathetic nervous system. However, there are important 
differences for instance in the pathways involved in driving lipolysis. 
Catecholamine-induced lipolysis occurs as mentioned in the introduction by activation of 
specific β-adrenergic receptors. There are four types of adrenergic receptors β1, β2, β3 and 
2A. In humans, β1 and β2 adrenergic receptors are most active, whereas the β3-adrenergic 
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receptor is the most active in mice. The 2A-adrenergic receptor is coupled to inhibitory G-
proteins and, when activated, the adenylyl cyclase is inactivated and lipolysis is inhibited. 
The α2-adrenergic receptor inhibitory pathway does not exist in rodents AT (51); therefore, 
when studying adrenergic receptor signalling, the lacking of inhibitory α2-adrenergic 
receptor signalling could account for differences between species. 
3.2.4.4 Energy expenditure 
The energy expenditure in a small animal such as the mouse is much higher than in 
humans, and this needs to be taken into consideration when using mice as a model system 
for human disease (159). The lipid turnover in mice is also different from that in humans.  
In mice, BAT has a significant impact on thermoregulation and energy expenditure (20). 
The relationship between surface and volume is different between mice and humans which 
account for the lower thermal dispersion in humans (13). It is, however, unclear what 
impact BAT has in human energy homeostasis, although several studies have reported its 
presence and activity in adult humans (28, 29, 160). It is estimated that, in adults, fully 
activated BAT can increase energy expenditure by up to 20%, which makes it an interesting 
target for obesity treatment in humans (13). 
Nevertheless, the translation of results from rodent studies of BAT to humans needs to be 
carefully considered since this particular fat depot clearly has different physiological impact 
in mice and humans. 
3.2.5 Knockout mice  
The generation of the TSHR adipocyte-specific (TSHRloxP/loxP Cre) knockout (KO) mouse 
strain used in the study was bred on a C57Bl6 background as previously described (123). In 
brief, a Cre-mouse strain expressing the Cre-recombinase under the control of the 
Fabp4/ap2-promoter was purchased from Jackson Laboratories ((B6.Cg-Tg (Fabp4-Cre) 
1Rev/J stock no. 005069 Jackson Laboratory) and bred with mice in which the LoxP-sites 
had been inserted in exon 10, encoding the transmembrane -subunit of the TSHR. As 
untreated controls, we used corresponding C57Bl6/J mice. 
The Cre-Lox system was first used in 1985 when Brian Sauer introduced the system in 
eukaryotic cells (161, 162). The Cre-Lox system is a method used to generate tissue-
specific gene knockout by deleting a part of a gene, thereby inhibiting the synthesis of a 
functional protein.  
More recent research has shown that the Fabp4/aP2-Cre used in this mouse strain is not as 
effective or specific as for example the adiponectin-Cre-lox system (163). This is seen by 
the effectivity of a 40-45% knockout of TSHR expression in these mice, due to the Cre-
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recombinase not being expressed in all adipocytes. However, considering the effects seen 
on body weight development and body temperatures, the smaller and more variable degree 
of knockout does have a significant effect in vivo and thus allows us to study the effect of 
TSHR removal in AT. One might also argue that a partial knockout phenotype better 
reflects a pathophysiological condition, since in most conditions such as obesity, TSHRs 
are reduced but not missing. 
3.2.6 Gene expression 
In Study II and III, quantitative real-time polymerase chain reaction (qRT-PCR) was used 
to quantify transcripts of interest. Briefly, total mRNA is extracted from a sample of cells or 
tissue. It is then reverse transcribed into complementary DNA (cDNA). The cDNA is 
amplified in the qRT-PCR reaction. Detection is enabled by fluorescence labelling of the 
probe or binding dye of primers depending on what assay is used.  
Gene expression is calculated by the delta-delta Ct method (153). The expression of a target 
gene is normalized to the expression of an endogenous control, also known as 
housekeeping gene and expressed as fold-change relative to an untreated control sample. 
The purpose of the endogenous control is to normalize the PCR for the amount of RNA in 
the reaction.  
There are some important aspects to considered when conducting PCR to investigate gene 
expression. It is a highly sensitive method which allows generation of a product when the 
target mRNA is present at very low levels. Also, the presence of a transcript product does 
not necessary correspond to corresponding levels of the functional protein. Furthermore, 
PCR is often applied in tissue which are heterogenous and the expression of the target 
cannot be attributed to a specific cell type. 
In study II and III qRT-PCR was conducted in adipocytes to ensure adipocyte-specific 
analysis. A limitation in our studies was that we did not verify the expression by 
quantification of protein levels. We did however, analyse adipocyte specific functions to 
assess if the observed gene expression had a functional impact on the phenotype. In study II 
we measure glucose tolerance and body temperature and in study IV we analyzed glycerol 
release in cell culture medium for assessment of lipolysis.  
3.3 STUDY III 
In study III, candidate genes for fasting serum insulin were identified from SNPs identified 
and listed in a GWAS meta-analysis (144). The identified candidate genes were 
functionally evaluated in a human mesenchymal stem cell model where hMSCs were 
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differentiated into adipocytes after knocking down genes with siRNA. The workflow is 
described in Figure 3.2.  
 
 
 
Figure 3.2. Schematic description of the workflow in Study III. 
3.3.1 Study participants in human WAT studies 
Studies III and IV included 114 non-diabetic Swedish women with WAT global 
transcriptome profile available from a previous study (142). The women were recruited 
by advertisement from the general adult population in the Stockholm (Sweden) area. They 
displayed a large inter-individual variation in BMI and were healthy, except that some 
were obese.   
3.3.2 Ethical permission 
The studies were performed in accordance with the guidelines set out by The Declaration 
of Helsinki. All participants received detailed information about the studies and written 
informed consent was obtained. The studies were approved by the regional ethics board in 
Stockholm (D. no. 278-03). 
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3.3.3 Experiments in white adipose tissue 
3.3.3.1 Lipolysis experiments 
In Studyies III and IV, lipolysis was measured using a bioluminescent method as described 
by Hellmer et al. (1989) (164) in mature adipocytes prepared from WAT biopsies. The cells 
were diluted in Krebs-Ringer phosphate buffer with bovine serum albumin (20 mg/ml), 
glucose (1 mg/ml) and ascorbic acid (0.1 mg/ml) and incubated with different 
concentrations of noradrenaline (10–12 to 10–4 mmol/l) for 2 hours at 37oC. Isoprenaline is 
a synthetic, selective β-adrenoreceptor agonist, and was used as the lipolytic agent. After 
incubation the samples were put on ice to stop lipolysis. A fat cell free aliquot was removed 
for the measurement of glycerol release with a luminometer, which measure light emitted in 
the following reactions: 
 
Luciferase and glycerol kinase compete for the use of ATP and a decreased emission of 
light indicates higher lipolytic activity. During lipolysis, each triglyceride molecule is 
broken down into three fatty acids and one glycerol molecule. Glycerol is a good marker 
for lipolysis since fat cells do not contain glycerol kinase and therefore are unable to reuse 
glycerol. 
3.3.3.2 Adipose morphology 
In Studies II and IV a measure of adipose tissue morphology was used to define whether 
the clinical WAT samples displayed hypertrophy or hyperplasia. Spalding KL (2008) and 
Arner E et al. (2010) (11, 42) have shown that the relationship between adipocyte volume 
across the range of fat mass is curve-linear. The difference between the actual measured 
adipocyte volume and the expected adipocyte volume from the mean curve fit is an 
indication of the adipose morphology independent of total body fat. A positive value 
indicates hypertrophy, whereas a negative value is indicative of hyperplasia.  
These morphology values can be quantitatively assessed and for the individuals included in 
Studies II and IV were obtained from previous calculations (165). Adipose morphology is a 
ATP + Glycerol
Glycerolkinase
Glycerol-1-phosphate + ADP
ATP + Luciferin + O2
Luciferase
Oxyluciferin + AMP + PPi + CO2 + Light
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good marker for adipocyte dysfunction given that hypertrophy is associated with attenuated 
insulin sensitivity. 
3.3.3.3 Lipogenesis experiments 
In Studies II and IV, insulin-stimulated lipogenesis was assessed as a measure for insulin 
sensitivity. Briefly, adipocyte lipogenesis was determined in isolated adipocytes which 
were incubated in vitro in an albumin-containing buffer with labeled [3H]glucose and  
unlabeled glucose and varying concentrations (0–70 nmol/l) of insulin. The incubations 
were conducted for 2 hours at 37°C with air as the gas phase. Incubations were stopped 
by rapidly chilling the incubation vials to 4°C. The incorporation of labelled glucose into 
adipocyte lipids was determined, which reflects lipogenesis, and was expressed as the 
amount of glucose incorporated per adipocyte number, as described previously (166). 
Values at the maximum effective insulin concentration were used. 
The method is used as a risk marker for IR, since a blunted ability of insulin to stimulate 
fat synthesis through glucose conversion into lipids (lipogenesis) leads to an influx of 
NEFA into the liver and to systemic IR.  
3.3.3.4 Adipose tissue depots 
In Studies II and IV, abdominal, subcutaneous AT (SAT) was used. In humans, an 
increased visceral AT (VAT) mass is associated with insulin resistance and dyslipidemias 
(167) SAT-derived adipocytes have a greater adipogenic capacity than VAT-derived 
adipocytes and are associated with improved or at least preserved insulin sensitivity. 
However, excessive abdominal SAT is also associated with a deranged metabolic profile 
(168). Understanding the growth mechanisms of SAT may reveal therapeutic targets for 
obesity-related metabolic disease. 
In Study III, visceral AT samples were not obtained for ethical reasons; it is a more 
invasive method to obtain visceral fat biopsies than subcutaneous fat samples obtained by 
needle aspiration under local anaesthesia. The results may only apply to subcutaneous fat; 
however, this depot constitutes >80% of the total fat mass and, through its mass effect, it 
has a major influence om body weight and energy homeostasis. 
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3.3.4 Expression quantitative trait locus (eQTL) analysis 
In Study III, eQTL-analysis was performed to link identified candidate genes from a 
GWAS to adipose tissue function. 
Today there are hundreds of identified SNPs that are associated with obesity traits such as 
BMI and fasting insulin, a marker for IR. The eQTL analysis is a method used to find the 
underlying genes affected by the associated SNP. A schematic overview of the theory 
behind eQTL analysis is presented in Figure 3.3. When a SNP affects a gene in the vicinity 
(+/- 500 kilo bases) in the genome, the term “cis” is used. If a SNP affects a gene further 
away, it is termed trans-eQTL. 
 
 
Figure 3.3. Expression quantitative trait loci (eQTL) analysis. A SNP discovered as 
associated with a disease trait in a GWAS, and also associated with the expression-level of 
a nearby gene (cis-eQTL).  
 
The expression of the nearby gene may or may not be the cause of the measured disease 
trait and the genes is therefore a candidate gene for disease. 
Since lead SNPs often resides in non-coding regions of the genome, eQTLs of genes in the 
vicinity of SNPs associated with obesity and obesity-related traits could lead to the 
discovery of candidate genes with a functional impact of disease (77).  
Identified genes from eQTL-analysis needs to be followed-up by functional analysis to link 
the gene with a genetic variant, and with a clinical trait. 
3.3.5 Human mesenchymal stem cells 
In Study III, hMSCs were differentiated in vitro and used to study the impact of knockdown 
of candidate genes on adipogenesis and adipocyte function. As well as the differentiation 
into mature adipocytes, hMSCs can be differentiated into myocytes, chondrocytes and 
osteocytes. Fibroblast growth factor 2 (FGF2) is added to the culture medium to stimulate 
proliferation followed by the induction of adipogenesis by adding rosiglitazone, insulin and 
T3.  
hMSCs cell lines are advantageous to use due to their ability to differentiate into an 
adipocyte phenotype with lipolytic response, insulin sensitivity and the secretion of 
SNP Disease trait
Cis regulation Gene
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adipokines (169, 170). The use of a cell line is also desirable when large number of cells are 
needed and when minor biological variation is desired. 
3.4 STUDY IV 
Study IV is based on two different cohorts which were recruited previously for studying the 
AT (142, 171). For the current study clinical parameters, AT phenotypes determined from 
adipose tissue biopsies, and gene expression analyzed by AT microarray, were analysed.  
3.4.1 Study design 
The main study cohort included 114 Swedish women (main study cohort) without diabetes 
which were recruited from the general adult population in the Stockholm (Sweden) area. 
Adipose tissue phenotypes (measures of lipolysis, adipose morphology, insulin sensitivity) 
were determined and associations with TSHR expression was analysed adjusted for age and 
BMI. 
Gene expression in WAT was analyzed by Gene 1.0 or 1.1 ST Affymetrix arrays as 
described (172) and associations of TSHR-expression and the expression of genes involved 
in adipogenesis, lipolysis and insulin signalling were also analysed. The cohort was 
previously described in detail elsewhere (142). 
In a second cohort of women with morbid obesity (n=16), TSHR expression was 
investigated before (obese group) and 2 years after bariatric surgery, when they had reached 
a non-obese state (post-obese group), and compared to matched never-obese controls 
(n=16). Abdominal subcutaneous AT biopsies were available before and after intervention 
for analysis of adipose tissue phenotypes and for microarray analysis. 
Women were recruited in association of planned visits to surgical units for gastric bypass 
surgery because of obesity or through local advertisement for the purpose of studying 
adipose factors regulating body weight. The post-obese women had reached their lowest 
post-surgery weight and had been weight stable at this weight for >6 months. Their mean 
BMI was 16 kg m-2 lower as compared with before surgery. The controls had also been 
weight-stable for >6 months.  
 
The local ethics committee approved the study, and written informed consent was obtained 
from all participants as described in Study III. 
3.4.2 WAT experiments 
The adipose tissue specimens (about 1 gram) was subjected to collagenase treatment to 
obtain isolated adipocytes as described (173). The mean weight and volume of these cells 
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were determined (172, 174), adipose tissue morphology, insulin-stimulated lipogenesis, 
spontaneous and hormone-stimulated lipolysis was assessed as described in section 3.3.1. 
Spontaneous unstimulated lipolysis in fat pads was also determined in adipose tissue 
explants as described (175). In brief, pieces of adipose tissue (200 or 300 mg) were 
incubated for 2 h (100 mg/ml) at 37°C with air as the gas phase in Krebs–Ringer phosphate 
buffer (pH 7.4) supplemented with glucose (8.6 mmol/l), ascorbic acid (0.1 mg/ml) and 
bovine serum albumin (20 mg/ml). Glycerol release into the medium was measured using a 
sensitive bioluminescence method and expressed as amount of glycerol release per 2 hours 
and 107 adipocytes. 
3.4.3 Statistical analysis 
In the main study cohort, multiple linear regression analyses was performed to investigate 
associations between TSHR expression and clinical parameters (BMI and AT phenotypes) 
and the expression of adipocyte specific genes. The beta-coefficient, partial regression 
coefficient represents the predicted change in the dependent variable when the predictor is 
increased by one unit while other predictors are held constant. Note that beta-coefficients 
depend on whether the dependent variable was log10-transformed. 
False discovery rate (FDR) <5% according to Benjamini and Hochberg (176) was used to 
adjust for the analysis of multiple parameters. 
In the bariatric surgery sub-group, one-way ANOVA with the Bonferroni posthoc test was 
performed to assess differences in TSHR expression between groups. A p-value of <0.05 
was considered significant. 
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4 RESULTS  
4.1 STUDY 1 
In Study I, we found that the TSH level in children with obesity was positively associated 
with BMI. We also found TSH level to be inversely associated with markers for insulin 
sensitivity and lipid metabolism (Table 4.1).  
 
Table 4.1. Associations of TSH with clinical parameters 
BMI SDS 0.21 (0.14–0.28)** 
Fasting insulin (mU/L) 0.77 (0.27–1.26)* 
Fasting glucose (mmol/L) 0.02 (-0.02–0.04) 
HOMA-IR 0.19 (0.06–0.31)* 
Total cholesterol (mmol/L) 0.05 (0.02–0.08)* 
Triglycerides (mmol/L) 0.06 (0.04–0.09)** 
LDL cholesterol (mmol/L) 0.01 (-0.02–0.04) 
HDL cholesterol (mmol/L) 0.01 (-0.000–0.02) 
Multivariable regression analysis of BMI SDS (independent variable) on TSH (dependent 
variable) adjusted for age and sex, and multivariable regression analysis of TSH 
(independent variable) on variables of lipid and glucose metabolism (dependent variable) 
controlling for age, sex and BMI SDS. Data is presented as beta coefficient (95% confidence 
interval), *p<0.05. **p<0.001. 
 
When children with high-normal and low-normal TSH levels were compared, higher BMI 
SDS was found in the group with high-normal TSH levels (2.92  0.45 vs 3.00  0.78) with 
no significant differences in fT3 or fT4-levels. 
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4.2 STUDY II 
In Study II, a transgenic mouse model, with reduced expression of TSHR in AT, was used. In 
the studied animals, TSHR-expression was reduced by 37% and 67% in WAT in mice fed a 
control and a high-fat diet, respectively. In BAT, TSHR-expression was reduced by 36% and 
42%, respectively (Paper II, Figure 1).   
We demonstrated that reduction of TSHR in WAT and BAT resulted in a greater weight gain 
in knockout mice than WT mice on both control diet and high-fat diet (Figure 4.1).  
 
 
Figure 4.1. Data are presented as mean weight per group and per week (grams). Error bars 
represent standard error of mean. Between-group comparisons using Independent t-test WT 
on control diet (CD) vs knockout on CD and WT on high-fat diet (HFD) vs knockout on HFD. 
*p<0.05, **p<0.01, ***p<0.001. 
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The body temperature was reduced in knockout mice before start and at the beginning of the 
study (Figure 4.2). 
 
Figure 4.2. Body temperature measured once weekly during weeks 1-3. Data are presented as 
mean temperature per group. Error bars represent 95% confidence intervals. Between group 
comparisons with one-way ANOVA. **p<0.01, ***p<0.001. 
 
The difference was not as clear at the end of the study period where a statistically significant 
difference was observed only at week 20 but not at week 18 and 19. We cannot rule out that 
temperatures could still be lower in KO mice. Due to limited power, statistical significance 
should be interpreted with care. The reduced expression of UCP1 at the end of the study 
indicate that thermoregulation is affected by the TSHR knockout throughout the study period. 
 
Glucose tolerance was assessed in female mice by an oral glucose tolerance test. Results 
showed that knockout mice on control diet had a reduced glucose tolerance compared to wild-
type mice at follow-up but not at baseline (Figure 4.2a–b). Furthermore, gene expression of 
both insulin receptor substrate 1 (IRS1) and Solute carrier family 2 member 4 (SLC2A4), was 
down-regulated which are genes involved in the insulin signalling cascade and glucose 
transport, respectively (Paper II, Figure 6a).  
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Figure 4.2a. Glucose tolerance test at follow-up. Data is presented as blood glucose 
(mmol/L). Error bars represents 95% confidence intervals. Figure 4.2b. Data is presented as 
area under the curve at baseline and after 10 weeks on high-fat or control diet. Error bars 
represents 95% confidence intervals. Between group comparisons using independent sample 
t-test between WT CD vs KO CD and WT HFD vs KO HFD, respectively. *p<0.05, **p<0.01. 
 
An overview of the directions of gene expressions affected by the knockout is given in Figure 
4.3. In white adipocytes, peroxisome proliferator-receptor gamma (PPARG) and 
CCAAT/enhancer-binding protein alpha (CEBPA), which are genes central to adipogenesis, 
were down-regulated in KO mice and in WT mice on high-fat diet as well, but significantly 
lower in KO mice on high-fat diet (Paper II, Figure 6a). 
Adrenergic signalling, responsible for functions such as lipolysis, was affected in knockout 
mice. Gene expression of ß1-adrenergic receptor (ADRB1) and ß3-adrenergic receptor 
(ADRB3) was lower in knockout mice on the control diet and a similar reduction was 
observed in WT and KO mice on the high-fat diet (Paper II, Figure 6b).  
Expressions levels of the investigated adipokines and cytokines in WAT of the TSHR KO 
mice, were heterogenous. The expression of adiponectin (ADIPOQ) was reduced in KO mice 
on CD and further reduced on HFD whereas leptin expression (LEP) was markedly reduced in 
HFD TSHR KO mice (Paper II, Figure 6c). 
The pro-inflammatory markers chemokine ligand 2 (CCL2) and tumour necrosis factor alpha 
(TNF) were both up-regulated in KO mice on both diets, but interleukin 6 (IL-6) was only 
affected in high-fat diet mice where it was markedly increased (Paper II, Figure 6c). 
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Figure 4.3. Effect of TSHR knockout in white adipose tissue. 
Effect on gene expression relative to wild-type mice on control diet. Arrows indicate direction 
of relative expression in intervention groups. Expressions of genes not investigated are left 
blank. 
 
In brown adipocytes, as well as a reduced expression of UCP1, expression of peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1a) was upregulated when 
the TSHR was removed (Paper II, Figure 7a), as was the expression of ADIPOQ (Paper II, 
Figure 7b). Adipogenic genes, along with ADRB3 and glucose transporter type 4 (SLC2A4) 
were down-regulated in a similar manner as in white adipocytes (Paper II, Figure 7a and b).  
  
Adipose tissue-specific TSHR knockout
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4.3 STUDY III 
4.3.1 Fasting serum insulin and adipose phenotypes 
The women in the clinical cohort displayed a wide variation in BMI and FSI (Paper III, 
Table 1), and as expected, BMI was positively correlated with FSI 
(r2 = 0.48, p = 2.0 × 10−17). BMI was also positively correlated with adipose spontaneous 
lipolysis (r2 = 0.15, p = 0.0002) and inversely correlated with insulin-stimulated lipogenesis 
(r2 = 0.08; p = 0.0038). There was no significant association with adipose morphology. FSI 
was positively correlated with adipose morphology (r2 = 0.15, p = 2.0 × 10−5) and 
spontaneous lipolysis (r2 = 0.23, p = 1.5 × 10−6) but was negatively correlated with insulin-
stimulated lipogenesis (r2 = 0.06, p = 0.0088). Associations between FSI and morphology 
(p = 1.3 × 10−6) or spontaneous lipolysis (p = 0.0019) remained significant after adjusting for 
BMI. 
From a GWAS meta-analysis, 17 genomic loci associated with fasting serum insulin (FSI) 
were identified. Out of 120 coding transcripts of genes within these 17 loci, 48 genes had 
expression levels associated with FSI, of which 11 remained significant after adjusting for 
BMI. To link the candidate genes for FSI to WAT function, we used an in silico method to 
determine whether tag-SNPs for each of the 17 loci comprised expression quantitative loci 
(eQTLs). According to the GTEx database, eight genes in four different loci demonstrated 
genotype specific expression (Table 4.2). 
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Table 4.2. SNPs from GWAS meta-analysis that comprise eQTLs 
Locus from FSI GWAS 
eQTL from GTEx 
portal 
Association with fasting serum insulin and adipose 
phenotypes (p-values) 
Chrom SNP Effect 
allele 
Gene P-value FSI Lipolysis Insulin-
stimulated 
lipogenesis 
Morphology 
2 rs2972143 G IRS1 8.0x10-08 2.8x10-
05 
  3.4x10-04 3.3x10-02 
4 rs3822072 A FAM13A 4.0x10-06 5.6x10-
12 
5.6x10-07 1.6x10-02 8.2x10-04 
6 rs6912327 T UHRF1BP1 2.0x10-25       1.1x10-02 
    T SNRPC 3.3x10-10         
7 rs1167800 A STAG3L1 3.3x10-10         
    A TRIM73 5.2x10-08 1.5x10-
02 
      
    A POM121C 3.6x10-07 2.0x10-
02 
  3.4x10-03 2.6x10-02 
    A PMS2P3 6.1x10-11   8.0x10-03   4.8x10-02 
Genes comprising eQTLs according to GTEx portal were analysed by linear regression 
with clinical phenotypes as dependent variables in respective analysis: fasting serum 
insulin (FSI), basal lipolysis, hormone-stimulated lipolysis adjusted for study batch, and 
morphology, adjusted for age.  
 
 
Four of the genes (FAM13A, UHRF1BP1, SNRPC and POM121C), were expressed in white 
adipocytes and was not previously described in connection to WAT function. They were 
taken forward for functional evaluation by siRNA knockdown in hMSCs. The cells were 
differentiated into adipocytes and the effect on adipocyte function was evaluated. 
For FAM13A, knockdown resulted in increased expression of adipogenic regulators 
peroxisome proliferator-receptor gamma (PPARG) and CCAAT/enhancer-binding protein 
alpha (CEBPA), hormone sensitive lipase encoded by LIPE and glucose transporter type 4, 
encoded by SLC2A4 (Paper III, Figure 3a). Glycerol levels in cell medium were also 
increased. POM121C knockdown resulted in reduced expression levels of all investigated 
genes (PPARG, CEBPA, LIPE, SLC2A4) (Paper III, Figure 3b) and a reduced glycerol 
release. Knockdown of SNRPC resulted in markedly reduced expression of ADIPOQ, 
encoding the adipokine adiponectin, and SLC2A4. Expression of LIPE and CEBPA were 
slightly reduced (Paper III, Figure 3c). URF1BP1 knockdown resulted in an increase in a 
modest increase in expression of PPARG and CEBPA, early during the differentiation (day 7), 
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with no effect on Day 12 (Paper III, Figure 3d). The release of glycerol in medium was 
unaffected.  
4.4 STUDY IV  
In study IV, we report that the expression of TSHR, in subcutaneous abdominal AT, was 
inversely related to basal lipolysis but positively related to hormone-stimulated lipolysis, 
adjusted for BMI (Table 4.3). 
 
Table 4.3. Association of TSHR gene expression and adipose tissue phenotypes 
 STD B 95% CI P R2 
 LOG10 BASAL LIPOLYSIS 
TSHR  -0.28 -0.04–(-0.01) 0.01A 0.18 
BMI (kg/m2) 0.28 0.01–0.02 0.003A 
Age -0.16 -0.01–0.001 0.07 
Study batch 0.09 -0.04–0.15 0.34 
 
LOG10 ISOPRENALINE STIMULATED LIPOLYSIS 
TSHR  0.27 0.00–0.03 0.01A 0.12 
BMI (kg/m2) -0.18 -0.01–(0.00) 0.06 
Age 0.19 0.00–0.01 0.04 
Study batch -0.08 -0.10–0.04 0.42 
TSHR gene expression as independent variable, AT phenotypes as dependent variables in respective 
model. Models are adjusted for BMI, age and study batch. Results are presented as standardized beta 
coefficient (std B), 95% confidence interval (95% CI), p-value (P) and adjusted percentage of 
variance explained (R2). a indicate a significant result after adjustment for a false discovery rate of 5% 
(FDR<5%). 
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In human subcutaneous WAT, TSHR-expression was associated with genes central to 
lipolysis and insulin-signalling (Table 4.4). 
 
Table 4.4. Association analysis of TSHR expression in AT and adipocyte specific genes 
 Std B 95% CI P Adj R2 
PGC-1A 0.20 0.19–1.32 0.009a 0.50 
CEBPA 0.03 -1.34–2.22 0.63 0.73 
LIPE 0.19 2.67–11.10 0.002a 0.69 
ADRB1 0.16 -0.12–1.06 0.12 0.10 
ADRB2 0.05 -0.23–0.41 0.57 0.24 
ADRB3 0.23 0.19–2.45 0.022a 0.21 
SLC2A4 0.21 0.79–4.08 0.004a 0.58 
IRS1 0.10 0.75–2.72 0.001a 0.76 
ADIPOQ 0.10 -1.54–31 0.075 0.21 
LEP -0.03 -9.3–6.2 0.69 0.44 
Linear regression analysis of AT TSHR gene expression as independent variable, adipocyte-specific 
genes as dependent variables in respective model. Models are adjusted for BMI, age and study batch. 
Results are presented as standardized beta-coefficient (Std B), 95% confidence interval (95% CI), p-
value (P) and adjusted percent of variance explained (Adj R2). 
a False discovery rate (FDR) <5%. 
 
TSHR-expression was associated with the expression of adrenergic receptor ADRB3 in a positive 
direction, but not ADRB1 and ADRB2. No association between TSHR-expression and adipokines 
leptin and adiponectin was found.
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Furthermore, in the second cohort which underwent bariatric surgery, we found TSHR 
expression to be affected by the weight-loss (Figure 4.4). 
 
 
Figure 4.4.  Differences in mean TSHR expression between groups. 
One-way ANOVA with Bonferroni posthoc test between obese and post-obese groups. 
Independent t-test between controls and obese and post-obese groups, respectively..  
Error bars represent 95% confidence intervals, *p <0.01.  
 
 
TSHR expression in AT was significantly upregulated after weight loss by gastric bypass surgery, 
(mean difference 4.8, 95% CI (0.89–8.73), p=0.007). No difference was observed in TSHR expression 
comparing the control group with the intervention group either pre- or post-surgery.
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5 DISCUSSION 
5.1 STUDIES I, II AND IV 
In Study I, we found TSH-levels in children with obesity to be elevated and associated with 
risk markers for glucose metabolism and lipid profile. Further functional investigations in 
in study II, in our mouse model showed that partial removal of TSHR in AT led to modified 
expressions of genes central for adipocyte development and function. Our functional 
analysis thus supports that the associations of TSH-levels and metabolic risk markers, 
found in the cross-sectional cohort study may be of physiological relevance in humans. 
The causes of an elevated TSH in obesity, and underlying mechanisms are unclear. The 
elevation of TSH could be compensatory due to increased metabolism, or the disturbed 
production of thyroid hormones in the obese state, or due to obesity itself directly 
upregulating the release of TSH. It is possible that the increase in TSH, causes down-
regulation of TSHRs in the AT causing a peripheral resistance, contributing to adipocyte 
dysfunction and predisposes to weight gain. 
In Study II, we showed that TSH-TSHR signalling in adipocytes in mice is likely to have a 
role in body weight regulation mediated by the AT. We observed that animals partially 
lacking functional TSHRs in the AT were more susceptible to developing obesity than 
control mice. We also found that a reduced gene expression of TSHR in the AT predisposed 
the studied subjects to develop metabolic complications. Thus, the reduction of TSH-TSHR 
signalling in AT causes metabolic consequences, both via weight gain and via effects on 
adipose tissue gene expression, resulting in impaired adipocyte metabolism. 
In a previous study, knocking down TSHR in mouse 3T3-L1 preadipocytes was shown to 
delay cell differentiation, implicating the TSHR in the regulation of this process (120). 
Elgadi et al. (2010) (125) showed that, in the same mice strain as used here, partially 
knocking out TSHR in AT resulted in a greater adipocyte volume also suggesting a 
potential role for TSHRs in adipogenesis (125).    
The TSHR knockout mice displayed a decrease in expression of genes central to 
adipogenesis (PPARG and CEBPA) (39). The reduction in expression of both PPARG and 
CEBPA are in line with previous observations of a reduced adipogenesis when TSHRs are 
reduced (120, 121), strengthening the evidence of TSHRs having a regulatory role in 
adipogenesis.  
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The relationship between TSH and IR is currently unclear. Some studies in adults and 
children have found TSH-levels to be associated with markers for IR (177-179), whereas 
other studies reported a lack of association (180, 181). 
In our TSHR knockout model, glucose tolerance was in fact affected. We report that in 
older animals with reduced expression of TSHR, in conjunction with an oral glucose 
tolerance test, the expression of genes relevant for insulin signalling and glucose uptake 
were down-regulated. These findings may indicate a reduced insulin sensitivity in 
adipocytes with down-regulated TSHR expression.  
We did not find any difference in glucose tolerance between wild-type and knockout obese 
mice. Both mice strains on the high-fat diet displayed an IR phenotype which may be due to 
the fact that both groups were obese and obesity itself is a strong predictor of IR. 
 
In study IV, we set out to investigate how our findings translates to adult humans.  We 
investigated if TSHR-expression in WAT was related to BMI, adipose phenotypes and 
relevant adipocyte-specific genes. Firstly, TSHR-expression was inversely correlated with 
BMI and was down-regulated in AT, in the obese state, which we observed in both human 
and rodent adipocytes. In humans, TSHR-expression was up-regulated after weight loss. 
Weight-loss was not investigated in our mouse model but it is possible that the same up-
regulation could take place in rodent AT, although this would require further studies.  
It has previously been shown that the lipolytic effect of TSH in adult humans is minimal 
(59). The present data indicate that the effects of TSH on adipocyte function and regulation 
may be of importance in adults. 
5.1.1 TSHR in human white adipose tissue 
In human WAT, the expression of TSHR was investigated in relation to adipose 
phenotypes. A positive association was found between hormone-stimulated lipolysis and 
TSHR-expression, and basal lipolysis was inversely associated with TSHR-expression. A 
high basal and low stimulated lipolysis is reported to predict weight-gain (55). 
 If TSHR-expression is involved in the regulation of lipolysis and a higher TSHR expression 
is involved in the regulation of basal lipolysis, the weight gain in the TSHR KO mouse 
strain could be connected to the effects on lipolysis. 
Our findings in the knockout mice together with our findings in human WAT, indicate 
TSHRs to play a role in the regulation of lipolysis. despite that the direct lipolytic effect is 
negligible after the neonatal period. 
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This suggestion is further strengthened by the observation of TSHR expression in human 
WAT is correlated with the expressions LIPE encoding the lipolytic enzyme hormone 
sensitive lipase, independent of BMI. 
Partially lacking functional TSHRs may contribute to difficulties in coping with 
overfeeding due to impaired adipogenesis and altered lipolytic regulation. Down-regulated 
TSHRs could contribute to lipid retention and AT expansion. An impaired adipogenesis 
could also explain the reduced insulin sensitivity observed. 
Regarding inflammation, the TSHR knockout in mice resulted in an increased expression of 
pro-inflammatory cytokines. In obese mice, the expression of these cytokines was even 
more increased both in wild-type and knockouts. In the lean knockout mice, the increased 
expression of pro-inflammatory markers could be due to the increased cell size reported by 
Elgadi et al. (2010) (125). The pro-inflammatory response may suggest that subjects with 
reduced TSH-TSHR signalling in AT, could have a reduced ability to cope with excessive 
expansion of the AT. This in turn leads to an increased inflammatory response, 
predisposing them to metabolic complications mediated by the chronic low-grade 
inflammation observed in obesity.  
Taken together, our findings support the notion that TSHRs in AT, possibly by their 
regulatory role in adipogenesis, may have an impact on lipolysis and insulin sensitivity in 
humans and mice. 
5.1.2 TSHR in rodent brown adipose tissue 
An inverse correlation between the amount of brown adipose tissue, body mass index and 
percentage body fat has been reported (182). BAT activation is also suggested to increase 
energy expenditure in humans (31). In our mouse model, TSHR knockout resulted in a 
reduced body temperature compared to control mice, which is most likely is due to the 
observed reduction in UCP1-expression.  
PGC-1a is involved in mitochondrial biogenesis and is important for the thermogenic 
activity in BAT (183). Its expression in knockout mice was up-regulated which may be 
compensatory for the reduced UCP1-expression observed.  
Our results show that in our knockout model, a reduction of TSHR-expression in BAT, does 
in fact reduce body temperature and possibly also energy expenditure. This could explain 
the increased body weight gain observed. The relevance of BAT in humans was not 
addressed in this thesis and more research is needed to clarify what impact TSHRs have in 
human BAT.  
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5.1.3 Study III 
Given that obesity is a complex disease and the related metabolic complications are clearly 
caused by many different factors, we set out to find genes involves in the development of 
insulin resistance.  
In Study III, we found two candidate genes that could be linked to adipocyte dysfunction. 
We report that the expression of FAM13A was associated with a beneficial metabolic 
profile. FAM13A-expression was associated with decreased WAT lipolysis, and knockdown 
 of FAM13A resulted in increased lipolysis and expression of LIPE, which encodes 
hormone sensitive lipase, a rate-limiting enzyme in lipolysis (184). Previously, it has been 
shown that basal lipolytic activity is a strong determination of insulin sensitivity (175). The 
reduced expression of genes central to adipogenesis and adipocyte function, implicate 
FAM13A as having a regulatory role in adipogenesis. The underlying molecular 
mechanisms linking FAM13A to lipolysis are unknown and beyond the scope of this 
investigation. However, a recent study reported FAM13A to be reduced in adipose tissue 
of obese mice and to be involved in the insulin signalling pathway by inhibition of IRS1 
degradation, thereby promoting the intra-cellular insulin response (185). Insulin has an 
inhibitory effect on lipolysis in adipocytes. The regulatory role of FAM13A on enhancing 
the insulin signal in the cell could therefore promote the inhibition of lipolysis. 
The expression of POM121C is positively associated with insulin sensitivity and adipose 
hyperplasia. Given that adipose hypertrophy previously has been linked to impaired 
adipogenesis and IR (48), our findings are consistent with an insulin-sensitising function 
of POM121C. Knockdown early in the adipogenesis caused decreased expression of all 
adipocyte-specific markers suggesting that POM121C is necessary for adipogenesis. The 
reduction of gene expression of markers for adipocyte function, and the reduction of 
glycerol, is probably secondary to an impaired adipogenesis. POM121C encodes a 
nucleoporin and forms an important component of the nuclear pore complexes (186). It 
has not, to the best of our knowledge, previously been implicated in human metabolic 
disease. 
Functional analysis of SNRPC and UHRF1BP1 did not suggest that these genes underlie 
genetic control of FSI. For SNRPC, the FSI-associated allele was associated with 
higher SNPRPC expression, suggesting that SNRPC contributes to metabolic disease. 
However, the results from SNPRPC knockdown were consistent with an insulin-
sensitising function of SNRPC. Knockdown of UHRF1BP1 had marginal effects on 
markers for adipogenesis and adipocyte function, suggesting that UHRF1BP is not a 
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causative gene for FSI. Of note, expression of neither UHRF1BP nor SNPRPC was 
associated with WAT variables with FDR <5%. 
 
5.2 CONCLUDING SUMMARY 
Obesity is a complex disease with underlying causes ranging from environmental to genetic 
factors. Prevention and treatment thus require a multidisciplinary approach and research to 
elucidate the underlying biological pathways is necessary.  
In this thesis, TSH-TSHR-signalling in AT was investigated. Given that TSHRs have been 
shown to be reduced in AT in the obese state, our results suggest that TSH-TSHR 
signalling is required for a functional expansion of AT and, when impaired, may contribute 
to a blunted obesity-related insulin sensitivity. Furthermore, we report that TSHR-
expression is associated with a decreased basal lipolytic capacity and an increased 
hormone-stimulated lipolysis. Changes in lipolytic capacity is a result of dysfunctional 
adipocytes and may contribute to metabolic complications such as IR in peripheral tissues 
(48, 187). 
We also searched for candidate genes for fasting insulin, and we report that FAM13A and 
POM121C are candidate genes for fasting insulin and show them to have a potentially 
protective role in IR by inhibiting lipolysis and promoting adipogenesis, respectively. These 
candidate genes could thus be potential treatment targets for insulin resistance. 
  
In this thesis, factors that may contribute to adipocyte dysfunction in obesity were 
investigated. The herein investigated targets, TSHR-signalling and the newly identified 
genes for fasting insulin, may be important contributors in the multifactorial 
development of obesity and the related metabolic risk. 
5.3 FUTURE PERSPECTIVES 
The adipose tissue is obviously more than just an energy storing organ. In obesity, the 
physiological changes that occurs, as well as the underlying genetic control of metabolism, 
are important factors to consider when trying to elucidate the cause and consequences of 
obesity and the metabolic complications that follow. 
Several factors contribute to metabolic risk in obesity. Two possible contributing factors to 
adipocyte dysfunction are hormonal signalling and genetic variance. Associations of TSH 
and obesity as well as obesity-related metabolic disease are well documented although the 
functional impact of TSH leading to these risks is not clarified.  Further research targeting 
TSHR impact in the adipocyte is necessary in order to fully understand these associations. 
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The brown adipose tissue is considered a potential target for obesity treatment due to its 
energy consuming function, but few studies have investigated the functional impact of BAT 
in obesity treatment. Studies trying to recruit and activate brown adipocytes and triggering 
the activation of brown adipocyte markers in WAT, so called browning,  has been reported 
but much research is still needed before implementation of such treatment methods in 
human obesity. 
Genetic variants associated with metabolic traits in the obese state seem to act by causing 
adipocyte dysfunction and IR. IR is an essential factor contributing to obesity-related 
metabolic disease. Elucidating the functional impact of underlying genes to complex 
disease is an important part in understanding the mechanisms behind obesity and related 
comorbidities. These kind of genetic studies increases the potential of finding genetically 
supported therapeutic targets in obesity and IR. 
Current treatment methods for obesity focus on weight-loss and life-style changes, mostly 
with unsatisfactory results. The most effective treatment today is bariatric surgery. 
However, considering that bariatric surgery is an invasive method carrying the risk of 
complications, and also that most individuals with obesity does not meet the criteria for 
surgery, new treatment strategies are needed (188, 189). Perhaps focusing on the energy 
metabolism would provide a good complementary strategy.  
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